论文信息 - Cyclothiazide potentiates agonist responses at human AMPA/kainate receptors expressed in oocytes.

Cyclothiazide potentiates agonist responses at human AMPA/kainate receptors expressed in oocytes.

Cloned human AMPA/kainate subunits were functionally expressed in Xenopus oocytes. Cyclothiazide potentiated kainate-evoked currents by 682 +/- 122% (mean +/- S.E.M., n = 5), 1396 +/- 55% (n = 4), and 690 +/- 40% (n = 14) in oocytes expressing GluR1, GluR2, and GluR1 + GluR2 receptors, respectively. AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole proprionate)-induced currents were also potentiated by cyclothiazide. GYKI 52466 (1-(4-amino-phenyl)-4-methyl-7,8-methylendioxyl-5H-2,3-benzod++ + iazepine hydrochloride) attenuated cyclothiazide potentiation in all cases. Thus, modulatory sites for cyclothiazide and GYKI 52466 exist on individual human AMPA/kainate receptor subunits. Additionally, kainate appears to act as a desensitizing partial agonist at human GluR1 and GluR2 receptor subunits.

[1] Á. Pataki,et al. Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GYKI 52466. , 1989, European journal of pharmacology.

[2] B. O'dowd,et al. A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors , 1992, Nature.

[3] S. Ozawa,et al. Agonist- and subunit-dependent potentiation of glutamate receptors by a nootropic drug aniracetam. , 1992, Brain research. Molecular brain research.

[4] P. May,et al. Cyclothiazide Treatment Unmasks AMPA Excitotoxicity in Rat Primary Hippocampal Cultures , 1993, Journal of neurochemistry.

[5] J. Olney,et al. A benzodiazepine recognition site associated with the non-NMDA glutamate receptor , 1993, Neuron.

[6] L. Vyklický,et al. Hippocampal neurons exhibit cyclothiazide-sensitive rapidly desensitizing responses to kainate , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[7] D. Lodge,et al. Cyclothiazide reverses AMPA receptor antagonism of the 2,3-benzodiazepine, GYKI 53655. , 1993, European journal of pharmacology.

[8] M. Rogawski,et al. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses , 1993, Neuron.